These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31683411)

  • 21. Failure of researchers, reviewers, editors, and the media to understand flaws in cancer screening studies: application to an article in Cancer.
    Berry DA
    Cancer; 2014 Sep; 120(18):2784-91. PubMed ID: 24925345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of lead-time bias in estimates of relative survival for breast cancer.
    Andersson TM; Rutherford MJ; Humphreys K
    Cancer Epidemiol; 2017 Feb; 46():50-56. PubMed ID: 28027488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias.
    Lawrence G; Wallis M; Allgood P; Nagtegaal ID; Warwick J; Cafferty FH; Houssami N; Kearins O; Tappenden N; O'Sullivan E; Duffy SW
    Breast Cancer Res Treat; 2009 Jul; 116(1):179-85. PubMed ID: 18622697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Screening and early diagnosis of cancers: 2 ways for a same goal].
    Bourmaud A; Nourissat A; Chauvin F
    Rev Prat; 2010 Feb; 60(2):183-8, 190. PubMed ID: 20225552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for disease: making evidence-based choices.
    Fields MM; Chevlen E
    Clin J Oncol Nurs; 2006 Feb; 10(1):73-6. PubMed ID: 16482730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval.
    Chubak J; Burnett-Hartman AN; Barlow WE; Corley DA; Croswell JM; Neslund-Dudas C; Vachani A; Silver MI; Tiro JA; Kamineni A
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1517-1520. PubMed ID: 35916602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computer-aided system of evaluation for population-based all-in-one service screening (CASE-PASS): from study design to outcome analysis with bias adjustment.
    Chen LS; Yen AM; Duffy SW; Tabar L; Lin WC; Chen HH
    Ann Epidemiol; 2010 Oct; 20(10):786-96. PubMed ID: 20816316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An ongoing case-control study to evaluate the NHS Bowel Cancer Screening Programme.
    Massat NJ; Sasieni PD; Parmar D; Duffy SW
    BMC Cancer; 2014 Dec; 14():945. PubMed ID: 25495609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and evaluation of safety and effectiveness of novel cancer screening tests for routine clinical use with applications to multicancer detection technologies.
    Doubeni CA; Lau YK; Lin JS; Pennello GA; Carlson RW
    Cancer; 2022 Feb; 128 Suppl 4(Suppl 4):883-891. PubMed ID: 35133658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conundrums in screening for cancer.
    Miller AB
    Int J Cancer; 2010 Mar; 126(5):1039-46. PubMed ID: 19960430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Principles of Cancer Screening.
    Pinsky PF
    Surg Clin North Am; 2015 Oct; 95(5):953-66. PubMed ID: 26315516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations for cancer screening would be different if we measured endpoints that are valid, reliable, specific, and important to patients.
    Porzsolt F; Matosevic R; Kaplan RM
    Cancer Causes Control; 2020 Aug; 31(8):705-711. PubMed ID: 32415530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The assessment of lead time and length bias in the evaluation of screening programmes.
    Day NE
    Maturitas; 1985 May; 7(1):51-8. PubMed ID: 4021829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
    O'Brien KM; Mooney T; Fitzpatrick P; Sharp L
    Breast Cancer Res Treat; 2018 Nov; 172(1):133-142. PubMed ID: 30006795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. All-cause mortality in randomized trials of cancer screening.
    Black WC; Haggstrom DA; Welch HG
    J Natl Cancer Inst; 2002 Feb; 94(3):167-73. PubMed ID: 11830606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival.
    Duffy SW; Nagtegaal ID; Wallis M; Cafferty FH; Houssami N; Warwick J; Allgood PC; Kearins O; Tappenden N; O'Sullivan E; Lawrence G
    Am J Epidemiol; 2008 Jul; 168(1):98-104. PubMed ID: 18504245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ethical issues in colorectal cancer screening.
    van Dam L; Bretthauer M
    Best Pract Res Clin Gastroenterol; 2014 Apr; 28(2):315-26. PubMed ID: 24810192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of early diagnosis and treatment of cancer].
    Dong ZW; Qiao YL; Wang GQ
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):637-40. PubMed ID: 23159003
    [No Abstract]   [Full Text] [Related]  

  • 39. [Mass screening and early diagnosis of cancers. Which methods are efficient?].
    Chauvin F
    Rev Prat; 2010 Feb; 60(2):175-7. PubMed ID: 20225550
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cancer screening - principles, evaluation and implementation].
    Egger M; Zwahlen M; Cerny T
    Ther Umsch; 2013 Apr; 70(4):195-203. PubMed ID: 23535546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.